module 5 opiates and heroin Flashcards

1
Q

factors associated with risk of overdose or addiction

A
long acting or ER formula: overdose  
combo of opioid and benzo: overdose
long term use: overdose, addiction
age > 65: overdose
sleep disordered breathing: overdose 
renal or hepatic impairment: overdose
depression: overdose, addiction
substance use disorder: overdose, addiction
hx of overdose: overdose
adolescence: addiction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

dx criteria for opioid use disorder

A
inc. amount or longer than intended use
unable to cut down or control use
excessive time spent to obtain, use, recover
strong desire to use
interference of important obligations
continued use despite problems 
use of opioid in hazardous situation: drive
need for inc. dose for effects
withdrawal s/s with dose decrease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

naloxone use

A

opiate or heroin overdose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

naloxone AE

A
ventricular arrhythmia 
cardiac arrest
HTN/hypoTN
coma
encephalopathy
seizure
pulmonary edema
opioid withdrawal s/s
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

naloxone administration

A
intranasal
- Q2-3 min until response or EMT arrival
subQ
IV
IM
- large first pass 
- short half life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

opioids activate

A

my opioid receptors located on synaptic nerve terminals

- over time tolerance to euphoric effects occurs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

opioid withdrawal

A

enhanced GABA release from inhibitory interneurones results in inhibition of dopamine neurons, dysphoria.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

naltrexone MOA

A

partial mu opioid antagonist

- prevents high

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

medical detox 3 steps

A
  1. evaluation: screen and assess
  2. stabilization: assisting pt through intoxication and withdrawal, meds may be used,
  3. fostering readiness and entry into tx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

methadone MOA

A

mu-opioid agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

methadone uses

A

opioid detox

long-term relapse prevention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

methadone AE

A

risk of addiction, misuse/abuse
respiratory depression
QT prolongation, torsades
neonatal opioid withdrawal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

methadone and preg

A

risk of fetal harm, but benefits outweigh the risk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

methadone interactions

A

CYP450

benzos and other CNS depressants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

methadone administartion

A

oral, daily

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

buprenorephine MOA

A

partial mu receptor agonist

- prevents lower affinity drugs like morphine from binding

17
Q

buprenorephine AE

A

BB: use with other CNS depressants

  • sedation
  • respiratory depression
  • coma
  • death
18
Q

buprenorephine precaution

A

preg: prolong use in 3rd trimester -> neonatal withdrawal

19
Q

buprenorpherine administration

A

start 12-48hrs after last opioid: precipitate withdrawal

- prevents high and alleviates cravings

20
Q

buprenorphine/naloxone MOA

A

sublingual: naloxone inactivated, get full buprenorphine effect
injected: naloxone activated, prevents euphoria effect

21
Q

buprenorphine/naloxone use

A

detox opioid/heroin

maintenance tx

22
Q

buprenorphine/naloxone AE

A

precipitate or worsen withdrawal if receptor still occupied

23
Q

cannabis use disorder

A

significant impairment in function in two or more areas within a 12 month period

24
Q

cannabis behavior effect

A
anxiety
euphoria
impaired judgement
impaired motor coordination
social withdrawal
25
Q

cannabis physiologic effects

A

CNS depressant w/out respiratory depression

26
Q

cannabis drug interactions

A

CYP2C9

CYP3A4

27
Q

cannabis withdrawal s/s

A
mild
anxiety
depression
irritability
anorexia
nausea
insomnia